Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ASCO 2017—making adifference in cancer care with you

ASCO 2017—making adifference in cancer care with you editorial memo (2017) 10:187–189 https://doi.org/10.1007/s12254-017-0364-y Gabriel Rinnerthaler Received: 31 October 2017 / Accepted: 31 October 2017 / Published online: 15 November 2017 © Springer-Verlag GmbH Austria, part of Springer Nature 2017 For the 2017 annual meeting of the American Society adjuvant setting, this trial confirms that positive re- of Clinical Oncology (ASCO) 5817 abstracts had been sults in the neoadjuvant setting might also be cau- submitted and 2463 were finally selected for presen- tiously transferred to the adjuvant setting. This further tation. To spread this enormous gain of knowledge, supports drug development within neoadjvant trials new ways of information exchange become increas- where clinical endpoints can be reached faster and ingly important. With webcasts and news tickers, pre- with substantially fewer participants compared to the sentations at international congresses can be followed adjuvant setting. The results from the OlympiAD trial, at home. Furthermore, continuing medical educa- investigating the poly ADP ribose polymerase (PARP) tion events and published reviews illuminate the pre- inhibitor olaparib in patients with metastatic breast sented data from different perspectives. In this spe- cancer harboring breast cancer gene (BRCA) germline cial edition, Austrian specialists summarize the im- mutations, demonstrated a superiority of olaparib portant and most http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

ASCO 2017—making adifference in cancer care with you

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/asco-2017-making-adifference-in-cancer-care-with-you-2kzY1dulMX
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer-Verlag GmbH Austria, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0364-y
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2017) 10:187–189 https://doi.org/10.1007/s12254-017-0364-y Gabriel Rinnerthaler Received: 31 October 2017 / Accepted: 31 October 2017 / Published online: 15 November 2017 © Springer-Verlag GmbH Austria, part of Springer Nature 2017 For the 2017 annual meeting of the American Society adjuvant setting, this trial confirms that positive re- of Clinical Oncology (ASCO) 5817 abstracts had been sults in the neoadjuvant setting might also be cau- submitted and 2463 were finally selected for presen- tiously transferred to the adjuvant setting. This further tation. To spread this enormous gain of knowledge, supports drug development within neoadjvant trials new ways of information exchange become increas- where clinical endpoints can be reached faster and ingly important. With webcasts and news tickers, pre- with substantially fewer participants compared to the sentations at international congresses can be followed adjuvant setting. The results from the OlympiAD trial, at home. Furthermore, continuing medical educa- investigating the poly ADP ribose polymerase (PARP) tion events and published reviews illuminate the pre- inhibitor olaparib in patients with metastatic breast sented data from different perspectives. In this spe- cancer harboring breast cancer gene (BRCA) germline cial edition, Austrian specialists summarize the im- mutations, demonstrated a superiority of olaparib portant and most

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Nov 15, 2017

References

  • Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
    Hida, T
  • Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts)
    Gadgeel Shirish, M
  • Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032
    Hellmann Matthew, D
  • Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Minckwitz, G
  • Olaparib for metastatic breast cancer in patients with a Germline BRCA mutation
    Robson, M
  • Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study
    Rummel Mathias, J
  • First-line treatment of iNHL or MCL patients with BR or R‑CHOP/R-CVP: Results of the BRIGHT 5‑year follow-up study
    Flinn Ian
  • Radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL〉60 study of the DSHNHL
    Pfreundschuh Michael
  • Impact of denosumab (DMB) compared with zoledronic acid (ZA) on renal function in the treatment of myeloma bone disease
    Raje Noopur, S
  • Phase III study of aldoxorubicin vs investigators’ choice as treatment for relapsed/refractory soft tissue sarcomas
    Chawla Sant, P
  • Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): final results of SARC028 and biomarker analyses
    Burgess Melissa, A
  • A multi-center phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401)
    D’Angelo Sandra, P
  • Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer
    Noronha Vanita
  • Epacadostat plus pembrolizumab in patients with SCCHN: preliminary phase I/II results from ECHO-202/KEYNOTE-037
    Omid, H
  • LION: Lymphadenectomy in ovarian neoplasms—a prospective randomized AGO study group led gynecologic cancer intergroup trial
    Harter Philipp
  • Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer
    Ledermann Jonathan, A
  • Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy
    Mansoor Raza, M
  • An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (checkmate 358): efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers
    Hollebecque Antoine
  • Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): the IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration
    Shi Qian
  • Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial
    Al-Batran Salah-Eddin
  • Adjuvant capecitabine for biliary tract cancer: the BILCAP randomized study
    Primrose John, N